Understanding Biomarker Method Validation: Specificity & Selectivity – A Scientific Perspective

Introduction

The January 2025 FDA guidance suggests using PK validation approaches as a starting point, but our extensive experience implementing biomarker assays reveals why specificity and selectivity demand fundamentally different scientific approaches.

Understanding Traditional Drug Assay Validation

In drug concentration assays, specificity, and selectivity are demonstrated through straightforward spike recovery experiments. Specificity evaluates reference standard recovery in samples containing structurally similar molecules, while selectivity examines spike recovery of high and low concentrations in individual matrix samples. This works because we’re measuring a well-characterized drug product.

The Scientific Challenge of Biomarker Assays

Biomarker measurement presents a more complex scientific reality. When measuring endogenous molecules, we face challenges that spike recovery alone cannot address:

• Our calibrator materials often differ from the endogenous biomarker

• The biomarker may exist in multiple biological forms

• The measurement must demonstrate consistent performance across individuals, with biomarker assays requiring an evaluation of parallelism

Scientific Approaches to Biomarker Validation

Our experience in successful biomarker implementation has demonstrated that these parameters require specific approaches:

Specificity Assessment

The central question shifts from spike recovery to demonstrating that our critical reagents recognize both the standard calibrator material and the endogenous analyte similarly. This is accomplished through careful parallelism studies that confirm consistent recognition of both molecules by the assay’s critical reagents.

Selectivity Evaluation

Rather than focusing on spike recovery, selectivity for biomarker assays requires demonstrating parallelism across a range of dilutions in individual samples containing the endogenous analyte. This approach verifies that our method performs consistently across the biological diversity we’ll encounter in actual use.

Why This Matters

These scientifically driven approaches ensure we’re truly demonstrating our method’s ability to reliably measure the biomarker in its natural biological context – the ultimate goal of method validation.